|
Aim: rapidly provide drug candidates to treat victims of Covid-19. We will do this by applying our cutting-edge technologies and libraries to screen for viable active compounds that kill coronavirus. The strategy will employ phenotype screens (FPDD) that test for coronavirus inhibition using mouse (MHV-59) and human (OC43) virus as models for fast compound screening in cell culture. Direct-acting antivirals will also be sought via target-based screening (FBDD) as inhibitors of essential viral proteins of SARS-CoV-2.